Compare · NVO vs SION
NVO vs SION
Side-by-side comparison of Novo Nordisk A/S (NVO) and Sionna Therapeutics Inc. (SION): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SION operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 107.2x SION ($1.71B).
- Over the past year, NVO is down 34.2% and SION is up 212.3% - SION leads by 246.5 points.
- SION has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for SION).
- Company
- Novo Nordisk A/S
- Sionna Therapeutics Inc.
- Price
- $41.18+6.93%
- $37.97-1.07%
- Market cap
- $183.82B
- $1.71B
- 1M return
- +13.32%
- +2.48%
- 1Y return
- -34.24%
- +212.25%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 8
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest SION
- SEC Form 4 filed by Thompson Peter A.
- SEC Form 4 filed by Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.
- SEC Form 4 filed by Thompson Peter A.
- SEC Form 4 filed by Orbimed Advisors Llc
- Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
- Chief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $347,019 worth of shares (10,250 units at $33.86) (SEC Form 4)
- SEC Form S-8 filed by Sionna Therapeutics Inc.
- SEC Form S-3ASR filed by Sionna Therapeutics Inc.
- SEC Form 10-K filed by Sionna Therapeutics Inc.